← Patent-cliff monitor Loss of exclusivity November 2044 latest FDA-listed patent expiry
Company GLENMARK SPECIALTY SA
Drug detail Brand name RYALTRIS Active ingredient MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE Strength 0.025MG/SPRAY;0.665MG/SPRAY Dosage form SPRAY, METERED Route NASAL Modality Small molecule FDA approval January 2022 Marketing status RX
Listed patents Patent Expires Type 12653833 November 2044 product 12303635 April 2039 substance, product 11679210 September 2038 product 10548907 September 2034 use U-3297 11400101 September 2034 use U-3297 12064442 September 2034 use U-3297 10016443 September 2034 use U-3297 10517880 September 2034 product 9750754 September 2034 product 9078923 September 2034 product 10561672 September 2034 product 9370483 September 2034 product 10376526 September 2034 product 10765686 September 2034 use U-3295 9937189 September 2034 product 10758550 September 2034 use U-3296 10646500 September 2034 use U-3297
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.